ArticleOpen forum infectious diseases2025
Differential Impact of Pneumococcal Conjugate Vaccines on Hospitalized
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current evidence suggests that in young children with community-acquired alveolar pneumonia (CAAP), bacterial-viral coinfections (mostly respiratory syncytial virus [RSV]-pneumococcus coinfections) are more prevalent among hospitalized children than among outpatients and that RSV-pneumococcal coinfections are more frequently associated with non-PCV13 serotypes. Based on this background, we speculated that following pneumococcal conjugate vaccine [PCV] implementation, the decline of hospitalized CAAP episodes would be lower than that of outpatient episodes. Methods: This analysis was a part of an ongoing (since 2004) population-based, active surveillance in children < 5 years, including all CAAP visits to the pediatric emergency room in southern Israel. Community-acquired alveolar pneumonia was radiologically confirmed by consensus reading. Episodes were divided into hospitalized and those discharged without hospitalization (outpatients). We used a negative binomial regression model to evaluate PCV7/PCV13 impact by age and ethnic group using monthly and yearly incidence rates. Analyzed periods were pre-PCV (2004-2009), PCV7/PCV13 transition (2009-2011), early-PCV13 (2011-2015), and late-PCV13 (2015-2019). Results: Of 11 130 episodes, 3677 and 7633 were outpatients and hospitalized, respectively. Post-PCV incidence dynamics significantly diverged between the 2 study groups. (1) During the PCV7/PCV13 transition, outpatient rates significantly declined, but not those of hospitalizations. 2) During late-PCV13 period, a significantly greater decline was reached among outpatients (67%; 95% confidence interval [CI] 62%-71%) versus hospitalized (47%; 95% CI 41%-54%). This difference remained for all age and ethnic groups. Conclusions: The marked divergence in PCV impact between hospitalized and outpatient episodes is intriguing, but consistent with previous studies suggesting that hospitalized CAAP was associated with a lower proportion of PCV13 serotypes, in conjunction with viral-bacterial (mostly RSV-pneumococcus) coinfections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.